Medpace Holdings (MEDP) CEO sells 23,144 shares, reports 4.73M held via LLC
Rhea-AI Filing Summary
Medpace Holdings, Inc. President & CEO August J. Troendle reported open-market sales of Medpace common stock. On August 10, 2026, he sold 5,534 shares at a weighted average price of $601.53 per share in multiple transactions between $600.00 and $602.73. On August 11, 2026, he sold 17,610 shares at a weighted average price of $605.11 per share in multiple transactions between $600.09 and $608.185, all pursuant to a limit order placed during an open window period. He also reports 4,733,019 shares of common stock held indirectly through Medpace Investors, LLC, where he has sole voting and investment control but disclaims beneficial ownership except to the extent of his pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Seller: 23,144 shares
Net Sell
3 txns
Insider
Troendle August J.
Role
President & CEO
Sold
23,144 shs ($13.98M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F3 | 17,610 | $605.11 | $10.66M |
| Sale | Common Stock F1, F2 | 5,534 | $601.53 | $3.33M |
| holding | Common Stock F4 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 615,802 shares (Direct);
Common Stock — 4,733,019 shares (Indirect, By Medpace Investors, LLC)
Footnotes (4)
- F1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
- F2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.00 to $602.73. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- F3. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.09 to $608.185. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- F4. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Key Figures
Shares sold 2026-08-10: 5,534 shares
Price 2026-08-10: $601.53 per share
Shares sold 2026-08-11: 17,610 shares
+3 more
6 metrics
Shares sold 2026-08-10
5,534 shares
Open-market sale of common stock at weighted average price
Price 2026-08-10
$601.53 per share
Weighted average sale price; trades from $600.00 to $602.73
Shares sold 2026-08-11
17,610 shares
Open-market sale of common stock at weighted average price
Price 2026-08-11
$605.11 per share
Weighted average sale price; trades from $600.09 to $608.185
Total shares sold
23,144 shares
Net reported sales of Medpace common stock across two days
Indirect holdings via LLC
4,733,019 shares
Common stock held indirectly through Medpace Investors, LLC
Key Terms
limit order, weighted average price, indirectly beneficially own, pecuniary interest
4 terms
limit order financial
"transactions were effected pursuant to a limit order placed by the Reporting Person"
A limit order is an instruction to buy or sell a stock only at a specific price or better, giving you control over the exact price you pay or receive. It matters to investors because it acts like a price guard—similar to setting a maximum you’ll pay for an item at a store—so you avoid unexpected prices, though the trade may not happen if the market never reaches your limit.
weighted average price financial
"The reported price is a weighted average price. These shares were sold"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
indirectly beneficially own financial
"may be deemed to indirectly beneficially own the securities of the Issuer held"
pecuniary interest financial
"disclaims beneficial ownership of such securities except to the extent of his pecuniary interest"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider stock sales did Medpace (MEDP) report for August 2026?
Medpace (MEDP) President & CEO August J. Troendle reported selling 23,144 shares of common stock on August 10–11, 2026, in open-market transactions at weighted average prices around $601.53 and $605.11 per share.
Were the Medpace (MEDP) insider sales made under a 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not marked as a plan. A footnote states the transactions were effected pursuant to a limit order during an open window period, rather than disclosing a Rule 10b5-1 trading plan.
What indirect Medpace (MEDP) holdings does the CEO report in this Form 4?
The CEO reports 4,733,019 shares of Medpace common stock held indirectly through Medpace Investors, LLC, where he has sole voting and investment control but disclaims beneficial ownership except for his pecuniary interest.
Is the Medpace (MEDP) CEO’s ownership through Medpace Investors, LLC direct or indirect?
The Form 4 shows indirect ownership of 4,733,019 shares held by Medpace Investors, LLC. A footnote explains he is the sole manager with voting and investment control but disclaims beneficial ownership beyond his pecuniary interest.